

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 27, 2003, 08:52:12 ; Search time 44 seconds

(without alignments)
626,884 Million cell updates/sec

Title: US-09-836-960-5

Perfect score: 1097
Sequence: 1 MYSAPSACTCLCHFLLCF.....PFKTYTVTKRSRRIRPTHPA 207

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

Listing first 45 summaries

A.Geneseq_101002.*
1: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1097	100.0	207	19	AAW57413
2	1097	100.0	207	20	AAW57413
3	1097	100.0	207	20	AAW57413
4	1097	100.0	207	21	AAW57413
5	1097	100.0	207	21	AAW57413
6	1097	100.0	207	21	AAW57413
7	1097	100.0	207	22	AAW57413
8	1097	100.0	207	22	AAW57413
9	1097	100.0	207	22	AAW57413
10	1097	100.0	207	22	AAW57413

11	1097	100.0	207	23	AAE18923	Human FGF-18 prote
12	1081	98.5	207	21	AAW56818	Rat fibroblast gro
13	1081	98.5	207	21	AAW56819	Mouse fibroblast g
14	1081	98.5	207	22	AAW56845	Murine fibroblast
15	1081	98.5	207	22	AAE04537	Human fibroblast g
16	932	85.0	194	21	AAW44843	Human heart specif
17	835	76.1	160	20	AAW39630	Human fibroblast g
18	686	62.5	130	23	AAW81309	Human FGF18 core s
19	596	54.3	215	19	AAW53024	Fibroblast growth
20	591	53.9	215	14	AAW16500	Alf1. Homo sap
21	591	53.9	215	16	AAW0783	Fibroblast growth
22	591	53.9	215	16	AAW0783	FGF-8. Homo sap
23	591	53.9	215	21	AAW0815	FGF-8. Homo sap
24	591	53.9	215	21	AAW0815	FGF-8. Homo sap
25	591	53.9	215	22	AAW0815	FGF-8. Homo sap
26	591	53.9	215	22	AAW0815	FGF-8. Homo sap
27	591	53.9	215	22	AAW0815	FGF-8. Homo sap
28	591	53.9	215	22	AAW0815	FGF-8. Homo sap
29	591	53.9	215	22	AAW0815	FGF-8. Homo sap
30	586	53.4	215	19	AAW5718	Human FGF-8 seq ID
31	586	53.4	215	21	AAW32340	Fibroblast growth
32	574.5	52.4	204	22	AAW7050	Human fibroblast g
33	571	52.1	216	22	AAW50272	hFGF-8 polypeptide
34	571	52.1	220	22	AAW50272	Human fibroblast g
35	571	52.1	220	23	AAW50272	Human fibroblast g
36	569.5	51.9	244	22	AAW47053	hFGF-8 polypeptide
37	568	51.8	216	19	AAW70330	Fibroblast growth
38	567.5	51.7	205	20	AAW13348	Amino acid sequenc
39	567.5	51.7	205	20	AAW05279	FGF-8 homologue PR
40	567.5	51.7	205	21	AAW43929	Human PRO187 prote
41	567.5	51.7	205	21	AAW8567	Human PRO187 prote
42	567.5	51.7	205	22	AAW12308	Human PRO187 polyp
43	567.5	51.7	205	22	AAW86552	PRO187. Homo sap
44	567.5	51.7	205	22	AAW1203	Amino acid sequenc
45	567.5	51.7	205	22	AAW80216	Human PRO187 prote

ALIGNMENTS

RESULT 1
AAW57413
ID AAW57413 standard; Protein: 207 AA.
AC AAW57413.
DT 24-SEP-1998 (first entry)
DE Amino acid sequence of fibroblast growth factor homologue zFGF-5.
XX Human: fibroblast growth factor homologue; zFGF-5; cardiac cell;
KW antagonist; antibody; heart failure; stroke; hypertension; cancer;
KW bone defects; arthritis; cardiac myocyte hyperplasia.
XX Homo sapiens.
XX WO9816644-A1.
XX 23-APR-1998.
XX 16-OCT-1997; 97WO-US18635.
XX 16-OCT-1996; 96US-0028646.
XX (ZYMO) ZYMOGENETICS INC.
XX Bukowski TR, Conklin DC, Delsher TA, Hansen B, Holderman SD;
PI Raymond FC, Sheppard PO;
XX WPI; 1998-251291/22.
XX N-PSDB; AAW29632.
XX New fibroblast growth factor homologue, zFGF-5 - used to develop

PT products for treating e.g. heart failure, stroke, hypertension, bone
 XX defects or cancers, arthritis, or wounds
 PS Claim 14; Page 75; p 94pp: English.
 XX
 CC This is the amino acid sequence of the novel fibroblast growth factor
 CC homologue zFGF-5, used in the method of the invention. The zFGF-5
 CC polypeptides can be used (optionally ex vivo) for enhancing the
 CC proliferation of cardiac tissue cells. The polypeptides, nucleic
 CC acids, antagonists, and antibodies can also be used in the treatment
 CC of disorders such as heart failure, stroke, hypertension, bone defects,
 CC cancer, arthritis, or wounds. The products can also be used in the
 CC study of cardiac myocyte hyperplasia and regeneration, to target
 CC delivery of agents to the heart and for detection and diagnosis. The
 CC recombinant cells can be used to produce the protein.
 XX
 SQ Sequence 207 AA:
 Query Match 100.0%; Score 1097; DB 19; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-111;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MYSAPSACTCLCHFLLCFOYOVVAEENVDRIRIHENOTRARDDVSRKOLRLYQYLSR 60
 Db 1 MYSAPSACTCLCHFLLCFOYOVVAEENVDRIRIHENOTRARDDVSRKOLRLYQYLSR 60
 QY 61 TSGKHIOVIGRRISARGEDGDKYAQLLVETDFGSOVRIRKGETEFLCMNRKGLVGRK 120
 Db 61 TSGKHIOVIGRRISARGEDGDKYAQLLVETDFGSOVRIRKGETEFLCMNRKGLVGRK 120
 QY 121 DGTSGKECVFIEKYLENNYTLALMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKRPK 180
 Db 121 DGTSGKECVFIEKYLENNYTLALMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKRPK 180
 QY 181 GQPELOKPFKYYTIVTKRSRRIRPTHPA 207
 Db 181 GQPELOKPFKYYTIVTKRSRRIRPTHPA 207
 RESULT 2
 AAY39628
 ID AAY39628 standard; Protein; 207 AA.
 XX
 AC AAY39628;
 XX
 DT 23-NOV-1999 (first entry)
 XX
 DE Human fibroblast growth factor 98 protein sequence.
 KW Fibroblast growth factor 98, FGF98; human; multipotent neural stem cell;
 KW progenitor cell; peripheral neuropathy; amyotrophic lateral sclerosis;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; dementia;
 KW ischaemic stroke; brain injury; acute spinal cord injury; infection;
 KW nervous system tumour; multiple sclerosis; epilepsy; metabolic disease;
 KW peripheral nerve trauma; retinitis pigmentosa; macular degeneration;
 KW retinal detachment; myocardial infarction; peripheral vascular disease;
 KW renal artery disease; diagnosis; therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO9946381-A2.
 XX
 PD 16-SEP-1999.
 XX
 PF 09-MAR-1999; 99WO-US05235.
 XX
 PR 09-MAR-1998; 98US-0077411.
 PR 29-APR-1998; 98US-0083553.
 PR 08-MAR-1999; 99US-0264851.
 XX
 XX (CHIR) CHIRON CORP.
 PA
 PI Cen H, Garcia PD, Grieshammer U, Kassam A, Lee PP, Pot D;

PI Gospodarowicz D, Martin K;
 XX
 DR WPI: 1999-551410/46.
 DR N-PSDB; AA220593.
 XX
 PT New polynucleotide encoding a fibroblast growth factor, useful for
 PT treating peripheral neuropathy, Alzheimer's disease, ischaemic stroke,
 PT brain or spinal cord injury, nervous system tumours, multiple sclerosis
 PT or epilepsy -
 PS Claim 5; Page 60; 60pp: English.
 XX
 CC This sequence is the human fibroblast growth factor 98 (FGF98) of
 CC the invention. FGF98 can be used for the isolation, regeneration,
 CC proliferation, and differentiation of mammalian multipotent neural stem
 CC cells, progenitor cells and progeny. Primary central (CNS) and peripheral
 CC nervous system (PNS) cells when treated with FGF98 proliferate, have at
 CC least a limited self regeneration capacity, and can undergo lineage
 CC restriction in response to the local environment. The FGF98 sequences can
 CC be used for providing trophic support for cells in a patient. They be
 CC used to treat e.g. peripheral neuropathy, amyotrophic lateral sclerosis,
 CC Alzheimer's disease, Parkinson's disease, Huntington's disease, ischaemic
 CC stroke, brain injury, acute spinal cord injury, nervous system tumours,
 CC multiple sclerosis, infection, dementia, epilepsy, peripheral nerve
 CC trauma or injury, exposure to neurotoxins, metabolic diseases, disorders
 CC of insufficient blood cells, retinitis pigmentosa, age-related macular
 CC degeneration, retinal detachment, myocardial ischaemia/infarction,
 CC peripheral vascular disease, renal artery disease and wound healing.
 CC Cells produced by treatment with FGF98 are also used to screen drugs and
 CC growth factors, which may affect development, differentiation, survival
 CC and/or function of CNS and PNS derived neurons and glia. FGF98 can also
 CC be used for the production of large amounts of otherwise minor
 CC populations of cells to be used for generation of cDNA libraries for the
 CC isolation of rare molecules expressed in precursor cells or progeny;
 CC cells produced by treatment may directly express growth factors or other
 CC molecules.
 XX
 SQ Sequence 207 AA:
 Query Match 100.0%; Score 1097; DB 20; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-111;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MYSAPSACTCLCHFLLCFOYOVVAEENVDRIRIHENOTRARDDVSRKOLRLYQYLSR 60
 Db 1 MYSAPSACTCLCHFLLCFOYOVVAEENVDRIRIHENOTRARDDVSRKOLRLYQYLSR 60
 QY 61 TSGKHIOVIGRRISARGEDGDKYAQLLVETDFGSOVRIRKGETEFLCMNRKGLVGRK 120
 Db 61 TSGKHIOVIGRRISARGEDGDKYAQLLVETDFGSOVRIRKGETEFLCMNRKGLVGRK 120
 QY 121 DGTSGKECVFIEKYLENNYTLALMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKRPK 180
 Db 121 DGTSGKECVFIEKYLENNYTLALMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKRPK 180
 QY 181 GQPELOKPFKYYTIVTKRSRRIRPTHPA 207
 Db 181 GQPELOKPFKYYTIVTKRSRRIRPTHPA 207
 RESULT 3
 AAY08590
 ID AAY08590 standard; Protein; 207 AA.
 XX
 AC AAY08590;
 XX
 DT 05-AUG-1999 (first entry)
 XX
 DE Human FGF-18 protein fragment.
 KW FGF-18; fibroblast growth factor; human; diagnosis; treatment;
 KW tumour; neoplastic cell growth; cell proliferation; tumorigenesis; cancer;
 KW autocrine signalling; Fgf-18.

XX OS Homo sapiens.
 XX KM WO9927100-A1.
 XX PN 03-JUN-1999.
 XX PD 25-NOV-1998; 98WO-US25190.
 XX PF 21-SEP-1998; 98US-0158432.
 XX PR 25-NOV-1997; 97US-0066840.
 XX PA (GETH) GENENTECH INC.
 XX PI Rotstein D, Goddard A, Gurney AL, Hillan KJ, Lawrence DA;
 XX PI Roy MA;
 XX DR WPI; 1999-347718/29.
 XX PT Nucleic acid encoding fibroblast growth factor - 19, useful for the
 XX PT diagnosis, prevention and treatment of cancers
 XX PS Disclosure; Fig 11; 88pp; English.
 XX CC This invention describes a novel human fibroblast growth factor, PRO533,
 XX CC also known as fibroblast growth factor-19 (FGF-19). The nucleic acids,
 XX CC methods and PRO533 polypeptides disclosed may be used in the diagnosis
 XX CC and treatment of tumours and/or conditions characterized by modulation of
 XX CC PRO533 expression, or in the preparation of compositions for such
 XX CC therapies. These compositions and methods may be used in the diagnosis
 XX CC and treatment of neoplastic cell growth and proliferation in mammals
 XX CC (especially humans). The invention is based on the identification of
 XX CC genes that are amplified in the genome of tumour cells. Such gene
 XX CC amplification is expected to be associated with the over expression of
 XX CC the gene product and contribute to tumourgenesis and/or autocrine
 XX CC signalling. Accordingly, the proteins encoded by the amplified genes are
 XX CC believed to be useful targets for the diagnosis and/or treatment of
 XX CC certain cancers and may act as predictors of the prognosis for tumour
 XX CC treatments.
 XX SO Sequence 207 AA;
 Query Match 100.0%; Score 1097; DB 20; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-111;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MYSAPSACTGCLHFLLCFQOVYVAEENVDFRIHVENOTRADVSRKQLRYQLYSR 60
 DB 1 MYSAPSACTGCLHFLLCFQOVYVAEENVDFRIHVENOTRADVSRKQLRYQLYSR 60
 QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTSGQVRIRIKETEFLICMNRKGLVGP 120
 DB 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTSGQVRIRIKETEFLICMNRKGLVGP 120
 QY 121 DGTSGKECVFTEKYLENNYATLMSAKYSGWYVGFKKGRPKRPKTRNODVHMKRYPK 180
 DB 121 DGTSGKECVFTEKYLENNYATLMSAKYSGWYVGFKKGRPKRPKTRNODVHMKRYPK 180
 QY 181 GQPELQKPFKYYTVTKRSRIRPTHPA 207
 DB 181 GQPELQKPFKYYTVTKRSRIRPTHPA 207
 RESULT 4
 AA87857
 ID AAY87857 standard; protein; 207 AA.
 XX AC AAY87857;
 XX DT 01-SEP-2000 (first entry)
 XX DE Human FGF-98 protein fragment.
 XX

KM FGF-98; fibroblast growth factor; cardiant; treatment; angiogenesis;
 KM coronary artery disease; myocardial infarction injury; human.
 XX OS Homo sapiens.
 XX KM WO200021548-A2.
 XX PN 20-APR-2000.
 XX PD 13-OCT-1999; 99WO-US22936.
 XX PF 13-OCT-1998; 98US-0104103.
 XX PR (CHIR) CHIRON CORP.
 XX PA (WHIT/) WHITEHOUSE M J.
 XX PI Kavanaugh WM;
 XX DR WPI; 2000-317840/27.
 XX PT Novel unit dose comprising fibroblast growth factor, its angiogenically
 XX PT active fragment or mutein for inducing cardiac angiogenesis, treating
 XX PT coronary artery disease and reducing post myocardial infarction injury
 XX PS Claim 1; Page 65-66; 67pp; English.
 XX CC This invention describes a novel unit dose (I), of fibroblast growth
 XX CC factor (FGF) comprising 0.008-6.1 mg of a mammalian FGF comprising
 XX CC sequence of 140 (II) and (III), 146 (IV) and (V), 205 (VI), 266
 XX CC (VII), 207 (VIII) and (XI), 215 (IX), and 208 (X) amino acids (aa),
 XX CC given in the specification, its angiogenically active fragment or
 XX CC mutein. The product of the invention has angiogenic and cardiant
 XX CC activity. (I) is used for treating a human patient for coronary artery
 XX CC disease, and inducing angiogenesis in the human heart. (I) further
 XX CC provides an adjunct for reducing post myocardial infarction injury in
 XX CC humans. The unit dose provides the human patient with a rapid and
 XX CC therapeutic cardiac angiogenesis sufficient to obviate surgical
 XX CC intervention and results in an superior increase in the treated
 XX CC patients' exercise tolerance time (ETT). It also provides a safe and
 XX CC therapeutically efficacious treatment for the patients with coronary
 XX CC artery disease that lasts at least 6 months before a further treatment
 XX CC is needed. The method provides superior increase of 1.5-2 minutes in
 XX CC the treated patient's (ETT), compared to an increase of 30 seconds for
 XX CC current modes treatment. This sequence represents the human FGF-98
 XX CC protein fragment described in the method of the invention.
 XX SO Sequence 207 AA;
 Query Match 100.0%; Score 1097; DB 21; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-111;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MYSAPSACTGCLHFLLCFQOVYVAEENVDFRIHVENOTRADVSRKQLRYQLYSR 60
 DB 1 MYSAPSACTGCLHFLLCFQOVYVAEENVDFRIHVENOTRADVSRKQLRYQLYSR 60
 QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTSGQVRIRIKETEFLICMNRKGLVGP 120
 DB 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTSGQVRIRIKETEFLICMNRKGLVGP 120
 QY 121 DGTSGKECVFTEKYLENNYATLMSAKYSGWYVGFKKGRPKRPKTRNODVHMKRYPK 180
 DB 121 DGTSGKECVFTEKYLENNYATLMSAKYSGWYVGFKKGRPKRPKTRNODVHMKRYPK 180
 QY 181 GQPELQKPFKYYTVTKRSRIRPTHPA 207
 DB 181 GQPELQKPFKYYTVTKRSRIRPTHPA 207
 RESULT 5
 AAY44844
 ID AAY44844 standard; Protein; 207 AA.

	XX	AAY44844;	
	AC		
	XX		
	DT	18-MAR-2000	(first entry)
	XX		
	DE	Human heart specific Fgf-8b protein (confirmed sequence).	
	XX		
	KW	Human; heart specific fibroblast growth factor-8b; FGF-8b; secreted protein; angiogenesis; anti-angiogenesis; cell differentiation; diagnosis; prognosis; screening; treat; cancer; ischemic heart disease; vascular.	
	XV		
	OS	Homo sapiens.	
	FH		
	FT	Key Peptide	Location/Qualifiers 1..27 /label= Signal_peptide
	FT	Protein	28..207 /label= Mature_Fgf-8b
	FT	Region	1..181 /note= "shows 80% homology with various human growth factors"
	FF		
	FN		
	PX	M020005369-AZ.	
	PD	03-FEB-2000.	
	XX		
	PE	20-JUL-1999;	99WO-US12839.
	XX		
	PR	20-JUL-1998;	98US-0093397.
	PR	10-SEP-1998;	98US-0150684.
	XX		
	PA	(CURA-) CURAGEN CORP.	
	PI		
	SH	Shimkets RA;	
	XX		
	DR	WPI: 2000-182696/16.	
	N-P	SDB: AA250351.	
	PT	Novel angiogenesis and anti-angiogenesis secreted proteins used to control angiogenesis -	
	PS	Claim 28; Fig 3B; 32pp; English.	
	CC	The present sequence is a confirmed sequence of heart specific fibroblast growth factor-8b (Fgf-8b), an angiogenesis/anti-angiogenesis secreted protein from human heart library. The protein exhibits angiogenic (either inducing or inhibiting) or cell differentiation activity. The present sequence can be used for diagnosis, prognosis, screening of CC and treating diseases and disorders associated with aberrant levels of the secreted protein. The protein can be used to control angiogenesis e.g., in cancers, Ischaemic heart and vascular diseases.	
	SQ	Sequence	207 AA;
OY		Query Match	100.0%; Score 1097; DB 21; Length 207;
DJ		Best Local Similarity	100.0%; Pred. No. 9.3e-111;
Dj		Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	I	MYSAPSACTCLLHLFLCFOVOVLAEENVDFRIHVENOTPARDDVSRODLTYOLTSR	60
Dj	I	MYSAPSACTGCHLPHLLCFQOVLVAEENDFRIHVENOTPARDDVSRODLTYOLTSR	60
OY	61	TSGNHIOVLGRIRISARGDGRKIAQLLVETDPFGSQVRIKGETEFYLCSNRRKGVLGKP	120
Dj	61	TSGNHIOVLGRIRISARGEDGRKYAOLLIVETDPFGSQVIKGETEFYLCMNRKKGLVGKP	120
OY	121	DGTKECEVFIFKVLENNNTALMSAKYSQGMYGTFTKGRPGRPKTRENODVDHEMKRYRK	180
Dj	121	DGTSECEVEFIKFVNLTALTMSAKYSGMVYGFTFKGRPGRPKTRENOOVHFMRKRYPK	180
OY	181	GQELQRPFKYYTVTKRSRLIPTHPA	207

```

Db      181  GQPELOKPFKYYTTKRSRRIRPTHPA 207
|||||
RESULT 6
AAV56817
ID      AAV56817 standard; Protein; 207 AA.
XX
AC      AAV56817;
XX
DT      31-MAR-2000 (first entry)
DE      Human fibroblast growth factor (FGF).
XX
KW      Fibroblast growth factor; FGF; tissue formation;
XX      Lung tissue interference; human.
OS      Homo sapiens.
XX
PN      JP1332570-A.
XX
PD      07-DEC-1999.
XX
PF      27-MAY-1998; 98JP-0145478.
XX
PR      27-MAY-1998; 98JP-0145478.
XX
PA      (SHIO ) SHIONOGI & CO LTD.
XX
DR      N-PSDB; AAV46767.
XX
PT      A new fibroblast growth factor and a gene coding it - useful for
PT      prevention, treatment and diagnosis of tissue formation interference or
PT      treatment of lung tissue interference
XX
PS      Claim 1; Page 7-8; 16pp; Japanese.
XX
CC      The invention provides fibroblast growth factor (FGF) proteins from
CC      human, rat and mouse. FGF is useful for prevention, treatment and
CC      diagnosis of tissue formation interference or treatment of lung tissue
CC      interference. The present sequence represents a human FGF.
XX
SQ      Sequence 207 AA:
XX
Query Match 100.0%; Score 1097; DB 21; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
QY      1 MVSASACTCLHLHFLLCFOYQVLAENVDFRIHVENQTRARDVSKRLIOLYSR 60
Db      1 MVSASACTCLHLHFLLCFOYQVLAENVDFRIHVENQTRARDVSKRLIOLYSR 60
QY      61 TSGKHIOVLGRRISARGEDGDKYAQLVETDTFGSOVRIGKETEFYLLCMNRKGLVGP 120
Db      61 TSGKHIOVLGRRISARGEDGDKYAQLVETDTFGSOVRIGKETEFYLLCMNRKGLVGP 120
QY      121 DGTSECVFIEVLENNNTALMSAKYSGHYVFTKKGRPKPKTRENQDVHFMKRIIPK 180
Db      121 DGTSECVFIEVLENNNTALMSAKYSGHYVFTKKGRPKPKTRENQDVHFMKRIIPK 180
QY      181 GQPELOKPFKYYTTKRSRRIRPTHPA 207
Db      181 GQPELOKPFKYYTTKRSRRIRPTHPA 207
RESULT 7
AAV65664
ID      AAV65664 standard; protein; 207 AA.
XX
AC      AAV65664;
XX
DT      07-JAN-2002 (first entry)

```

XX DE Human fibroblast growth factor (FGF)-18.
XX
KM Fibroblast growth factor; FGF; FGF-like polypeptide; mitogenic;
KM fat deposition; vulnerary; antidiabetic; dermatological; anorectic;
KM antidiabetic; antiinflammatory; cytosolic; hepatic; virucide;
KM neuroprotectant; pulmonary; gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN WO200172957-A2.
XX
PD 04-OCT-2001.
XX
PF 02-APR-2001; 2001WO-1B00664.
XX
PR 31-MAR-2000; 2000US-0540118.
XX
PA (ITOH/) ITOH N.
XX
PI Itoh N;
XX
DR WPI; 2001-611623/70.
XX
PT New human nucleic acid encoding fibroblast growth factor-like peptide,
PT useful for treatment and diagnosis of e.g. wounds and inflammatory
PT bowel disease -
XX
PS Disclosure; Fig 3; 172pp; English.
XX
XX The invention provides human nucleic acids encoding fibroblast growth
CC factor (FGF)-like peptide. The FGF-like polypeptides can be expressed by
CC standard recombinant methodology and are mitogenic for a wide range of
CC cells, inducing differentiation and proliferation, and inhibiting
CC deposition of fat. The FGF-like polypeptides, polynucleotides and
CC specific antibodies and modulators are useful for treating a very wide
CC range of diseases and conditions, e.g. wounds, ulcers, skin aging,
CC obesity, diabetes, alopecia, inflammatory bowel disease, emphysema, viral
CC hepatitis, multiple sclerosis, respiratory distress syndrome, tumors of
CC the eye, etc., also for maintaining organs before transplant and
CC supporting culture of primary cells and tissues. Sequences AAG5647-67
CC represent amino acid sequences of some members of the FGF family.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9, 3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTGCLHFLLCFQVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYOLYSR 60
DB 1 MYSAPSACTGCLHFLLCFQVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYOLYSR 60
QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSQVRIRIKETEFYLCNNRKGKLVGKP 120
DB 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSQVRIRIKETEFYLCNNRKGKLVGKP 120
QY 121 DGTSGKECVFTEKYLENNYITALMSAKYSGWYVGTGKGRPKGKPTRBNODVHFMKRYPK 180
DB 121 DGTSGKECVFTEKYLENNYITALMSAKYSGWYVGTGKGRPKGKPTRBNODVHFMKRYPK 180
QY 181 GPELOKPFKYTYVTVKRSRIRIRPTHPA 207
DB 181 GPELOKPFKYTYVTVKRSRIRIRPTHPA 207

RESULT 8
AAB85827
ID AAB85827 standard; Protein; 207 AA.
XX
AC AAB85827;
XX
DT 29-OCT-2001 (first entry)

XX DE Human fibroblast growth factor (FGF)-17.
XX
KM Fibroblast growth factor; FGF; FGF-23; osteopathic; vulnerary; ADHR;
KM hepatocytic; autosomal dominant hypophosphatemic rickets; human;
KM angiogenesis; gene therapy; liver disorder; antisense therapy.
XX
OS Homo sapiens.
XX
PN WO200161007-A2.
XX
PD 23-AUG-2001.
XX
PF 15-FEB-2001; 2001WO-US04778.
XX
PR 15-FEB-2000; 2000US-0182442.
XX
PR 20-APR-2000; 2000US-0198903.
XX
PR 15-FEB-2001; 2001US-0748581.
XX
PA (AMGE-) AMGEN INC.
XX
PI Luethy R, Yang R, Suggs S, Sarosi D;
XX
DR WPI; 2001-514774/56.
XX
PT An isolated nucleic acid molecule encoding a fibroblast growth factor
PT 23 useful for treating autosomal dominant hypophosphatemic rickets -
XX
XX Example 1; Fig 2A-G; 158pp; English.
XX
XX The invention provides a human fibroblast growth factor (FGF)-23
CC polypeptide. The encoding DNA insert is contained in ATCC Deposit No.
CC PTA-1617. FGF-23 can be expressed by standard recombinant methodology.
CC The FGF-23 polypeptides, polynucleotides, modulators and antibodies are
CC useful for treating, preventing, or ameliorating an FGF-23 polypeptide-
CC related disease, condition or disorder especially autosomal dominant
CC hypophosphatemic rickets (ADHR). They are also useful for diagnosing a
CC pathological condition and for stimulating angiogenesis, promoting wound
CC healing and treating disorders of the liver. Sequences AAB85812-29
CC represent human FGF protein sequences used for comparison studies with
CC FGF-23.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9, 3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTGCLHFLLCFQVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYOLYSR 60
DB 1 MYSAPSACTGCLHFLLCFQVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYOLYSR 60
QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSQVRIRIKETEFYLCNNRKGKLVGKP 120
DB 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSQVRIRIKETEFYLCNNRKGKLVGKP 120
QY 121 DGTSGKECVFTEKYLENNYITALMSAKYSGWYVGTGKGRPKGKPTRBNODVHFMKRYPK 180
DB 121 DGTSGKECVFTEKYLENNYITALMSAKYSGWYVGTGKGRPKGKPTRBNODVHFMKRYPK 180
QY 181 GPELOKPFKYTYVTVKRSRIRIRPTHPA 207
DB 181 GPELOKPFKYTYVTVKRSRIRIRPTHPA 207

RESULT 9
AAE04536
ID AAE04536 standard; Protein; 207 AA.
XX
AC AAE04536;
XX
DT 10-SEP-2001 (first entry)

DE Human fibroblast growth factor (zFGF5).
XX
KW Human; fibroblast growth factor-18; FGF-18; zFGF5; FGF receptor-2;
KW FGF receptor-3; cytoxin; cell proliferation inhibitor; tumour;
KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
KW thyroid carcinoma; osteosarcoma.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..27
FT /label= Signal_peptide
FT 28..207
FT Protein /note= "Human mature fibroblast growth factor (zFGF5)"
XX
PN WO200139788-A2.
XX
PD 07-JUN-2001.
XX
PF 28-NOV-2000; 2000MO-US32380.
XX
PR 02-DEC-1999; 99US-0452977.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI West JW;
XX
DR WPI; 2001-417789/44.
DR N-PSDB; AAD07795.
XX
XX
PT Novel fibroblast growth factor targeting composition useful for
PT inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
PT receptor 2 -
XX
PS Claim 3; Page 59; 62pp; English.
XX
CC The present invention relates to methods for targeting cells that
CC express fibroblast growth receptor-3 or -2. Fibroblast growth
CC factor-18 (FGF-18) binds with FGF receptor-2 and -3. A targeting
CC composition comprising FGF-18 component and cytoxin, is useful for
CC inhibiting the proliferation of cells that express FGF receptor-3 or
CC -2, in a subject having tumor cells such as multiple myeloma cells,
CC bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
CC cells, osteosarcoma cells and intestinal smooth muscle cells. The present
CC sequence is human zFGF5 protein.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKOLRLYLQLSR 60
Db 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKOLRLYLQLSR 60
OY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSGVRIKGETEFYLCMNRKGLVGR 120
Db 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSGVRIKGETEFYLCMNRKGLVGR 120
OY 121 DGTSGKECVFIEKVENNTALMSAKYSGWYVGTGKGRPRKGPRTRENOQDVHFMRKRPK 180
Db 121 DGTSGKECVFIEKVENNTALMSAKYSGWYVGTGKGRPRKGPRTRENOQDVHFMRKRPK 180
OY 181 GPELOKPFKTYTTVKRSRIRPTHPA 207
Db 181 GPELOKPFKTYTTVKRSRIRPTHPA 207
RESULT 10
AAU01240
ID AAU01240 standard; Protein: 207 AA.
XX

AC AAU01240;
XX
DT 16-JUL-2001 (first entry)
XX
XX Human fibroblast growth factor homologue, zFGF-5.
DE Human fibroblast growth factor homologue; zFGF-5; plasmid construction;
KW Human; fibroblast growth factor homologue; zFGF-5; plasmid construction;
KW homologous recombination.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..26
FT /label= Signal_peptide
FT 27..207
FT Protein /label= Mature_zFGF-5
XX
PN US6207442-B1.
XX
PD 27-MAR-2001.
XX
PF 15-OCT-1998; 98US-0173043.
XX
PR 16-OCT-1997; 97US-0062061.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Raymond CK;
XX
DR WPI; 2001-256851/26.
DR N-PSDB; AAS00951.
XX
XX
PT Preparing a double-stranded, circular DNA molecule, involves homologous
PT recombination of one or more donor DNA fragments encoding the protein
PT of interest, with an acceptor plasmid and DNA linkers in host cell -
XX
XX Example 5; Columns 27-30; 23pp; English.
XX
XX The sequence is a Human fibroblast growth factor homologue, zFGF-5,
XX used to demonstrate the method of the invention. The method of the
XX invention comprises preparing a double-stranded, circular DNA molecule,
XX comprising combining donor DNA fragments encoding the protein of interest
XX with an acceptor plasmid, and two DNA linkers in a Saccharomyces
XX cerevisiae host cell. The encoding DNA is linked to the acceptor plasmid
XX by homologous recombination of with the linkers and acceptor plasmid to
XX form the closed, circular plasmid. The obtained plasmid is useful for
XX transforming host cells and producing proteins of interest. The method
XX allows for production of a standardised plasmid into which a variety of
XX DNA sequences can be readily inserted and subsequently expressed.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKOLRLYLQLSR 60
Db 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKOLRLYLQLSR 60
OY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSGVRIKGETEFYLCMNRKGLVGR 120
Db 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFTGSGVRIKGETEFYLCMNRKGLVGR 120
OY 121 DGTSGKECVFIEKVENNTALMSAKYSGWYVGTGKGRPRKGPRTRENOQDVHFMRKRPK 180
Db 121 DGTSGKECVFIEKVENNTALMSAKYSGWYVGTGKGRPRKGPRTRENOQDVHFMRKRPK 180
OY 181 GPELOKPFKTYTTVKRSRIRPTHPA 207
Db 181 GPELOKPFKTYTTVKRSRIRPTHPA 207

RESULT 11
AAE18823
ID AAE18823 standard; Protein: 207 AA.
XX
AC AAE18823;
XX
DT 17-MAY-2002 (first entry)
XX
DE Human FGF-18 protein.
XX
KW Fibroblast growth factor; FGF-like protein; wound healing; bullous;
KW epidermolysis; erosive gastritis; inflammatory bowel disease; ulcer;
KW oesophagitis; Crohn's disease; hyaline membrane disease; emphysema;
KW pulmonary fibrosis; hepatic cirrhosis; liver failure; angiogenesis;
KW multiple sclerosis; neurodegenerative disease; lung abnormality;
KW viral hepatitis; respiratory distress syndrome; tumour; skin aging;
KW gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN US2002001825-A1.
XX
PD 03-JAN-2002.
XX
PF 02-APR-2001; 2001US-0822485.
XX
PR 31-MAR-2000; 2000US-0540118.
XX
PA (ITOH/) ITOH N.
XX
PI Itoh N;
XX
DR WPI; 2002-187704/24.
XX
PT Novel fibroblast growth factor-like polypeptide useful for treating,
PT ameliorating and/or preventing dermal wounds, gastric ulcer, Crohn's
PT disease and pulmonary inflammation
XX
XX
PS Disclosure; Fig 3; 63pp; English.
XX
XX The invention relates to fibroblast growth factor (FGF)-like
CC polypeptides and nucleic acid molecules encoding such polypeptides.
CC Sequences of the invention are useful for treating, preventing or
CC ameliorating a medical condition. They are useful for treating dermal
CC wounds, epidermolysis, bullous, male pattern alopecia, gastric ulcer,
CC duodenal ulcer, erosive gastritis, oesophagitis, oesophageal reflux
CC disease, inflammatory bowel disease, Crohn's disease, radiation- or
CC chemotherapy-induced gut toxicity, hyaline membrane disease, necrosis
CC of the respiratory epithelium, emphysema, pulmonary inflammation,
CC pulmonary fibrosis, hepatic cirrhosis, toxic insults to the liver,
CC fulminant liver failure, viral hepatitis, mucositis, multiple sclerosis
CC and other neurodegenerative diseases, infantile respiratory distress
CC syndrome, bronchopulmonary dysplasia, acute respiratory distress
CC syndrome or other lung abnormalities, tumours of the eye or the other
CC tissues and organs. FGF-like polypeptides are useful stimulating
CC angiogenesis, promoting wound healing, modulating differentiation of
CC neuronal cells, adipocytes and skeletal muscle cells, preventing or
CC ameliorate skin aging, preventing hair loss, stimulating the growth
CC and differentiation of haematopoietic cells and bone marrow cells and
CC maintaining organs before transplantation and for supporting cultures
CC of primary cells and tissues. Sequences of the invention are also
CC used in gene therapy and as vaccines. The present sequence is human
CC FGF-18 protein which is a member of the FGF family.
XX
SQ Sequence 207 AA:
Query Match 100.0%; Score 1097; DB 23; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 TSGKHIOVLGRRISARGEDGDKYAQLLVENDTFESQVRIKETEPEFLCMNRKGLVGP 120
DB 61 TSGKHIOVLGRRISARGEDGDKYAQLLVENDTFESQVRIKETEPEFLCMNRKGLVGP 120
QY 121 DGTSKCEVFTEKYLENNYTLMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMKRYPK 180
DB 121 DGTSKCEVFTEKYLENNYTLMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMKRYPK 180
QY 181 GPELOKPFKYTYTVTKRSRRIRPTHPA 207
DB 181 GPELOKPFKYTYTVTKRSRRIRPTHPA 207
RESULT 12
AAV56818
ID AAV56818 standard; Protein: 207 AA.
XX
AC AAV56818;
XX
DT 31-MAR-2000 (first entry)
XX
DE Rat fibroblast growth factor (FGF).
XX
KW Fibroblast growth factor; FGF; tissue formation;
KW lung tissue interference; rat.
XX
OS Rattus sp.
XX
PN JP1332570-A.
XX
PD 07-DEC-1999.
XX
PF 27-MAY-1998; 98JP-0145478.
XX
PR 27-MAY-1998; 98JP-0145478.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
DR WPI; 2000-091354/08.
DR N-PSDB; AA426768.
XX
PT A new fibroblast growth factor and a gene coding it - useful for
PT prevention, treatment and diagnosis of tissue formation interference or
PT treatment of lung tissue interference
XX
XX Claim 1; Page 8-9; 16pp; Japanese.
XX
XX The invention provides fibroblast growth factor (FGF) proteins from
CC human, rat and mouse. FGF is useful for prevention, treatment and
CC diagnosis of tissue formation interference or treatment of lung tissue
CC interference. The present sequence represents a rat FGF.
XX
SQ Sequence 207 AA:
Query Match 98.5%; Score 1081; DB 21; Length 207;
Best Local Similarity 99.0%; Pred. No. 5.1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 181 GQTELOKPKKYYTVTKRSRRIRPTHP 206

RESULT 13
AAV56819
ID AAV56819 standard; Protein; 207 AA.
XX
AC AAV56819;
XX
DT 31-MAR-2000 (first entry)
XX
DE Mouse fibroblast growth factor (FGF).
XX
KW Fibroblast growth factor; FGF; tissue formation;
KM lung tissue interference; mouse.
XX
OS Mus sp.
XX
PN JP11332570-A.
XX
PD 07-DEC-1999.
XX
PF 27-MAY-1998; 96BP-0145478.
XX
PR 27-MAY-1998; 96BP-0145478.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
DR WPI: 2000-091354/08.
DR N-PSDB: AA246769.
XX
XX
XX A new fibroblast growth factor and a gene coding it - useful for
PT prevention, treatment and diagnosis of tissue formation interference or
PT treatment of lung tissue interference
XX
PS Claim 1; Page 9-10; 16pp; Japanese.
XX
CC The invention provides fibroblast growth factor (FGF) proteins from
CC human, rat and mouse. FGF is useful for prevention, treatment and
CC diagnosis of tissue formation interference or treatment of lung tissue
CC interference. The present sequence represents a mouse FGF.
XX
SQ Sequence 207 AA:

Query Match 98.5%; Score 1081; DB 21; Length 207;
Best Local Similarity 99.0%; Pred. No. 5,1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MYSAPSACTCLCLHFLLLCFQYQVLYAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTCLCLHFLLLCFQYQVLYAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIQVGRIRISARGEGDGYAQLVETDFGSOVRIRKGETEFLYLCMNRKGLVGRP 120
DB 61 TSGKHIQVGRIRISARGEGDGYAQLVETDFGSOVRIRKGETEFLYLCMNRKGLVGRP 120
QY 121 DGTSECVFIEKVLNNYATALMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYPK 180
DB 121 DGTSECVFIEKVLNNYATALMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYPK 180
QY 181 GQPELOKPKKYYTVTKRSRRIRPTHP 206
DB 181 GQPELOKPKKYYTVTKRSRRIRPTHP 206

RESULT 14
AAB85845
ID AAB85845 standard; Protein; 207 AA.
XX
AC AAB85845;
XX
DT 29-OCT-2001 (first entry)
XX

DE Murine fibroblast growth factor (FGF)-17.
XX
KW Fibroblast growth factor; FGF; FGF-23; osteopathic; vulnery; ADHR;
KM hepatotropic; autosomal dominant hypophosphatemic rickets; mouse;
KW angiogenesis; gene-therapy; liver disorder; antisense-therapy.
XX
OS Mus musculus.
XX
PN WO200161007-A2.
XX
PD 23-AUG-2001.
XX
PF 15-FEB-2001; 2001WO-US04778.
XX
PR 15-FEB-2000; 2000US-0182442.
PR 20-APR-2000; 2000US-0198903.
PR 15-FEB-2001; 2001US-0748581.
XX
PA (AMGE-) AMGEN INC.
XX
PI Luethy R, Yang R, Suggs S, Sarosi D;
XX
DR WPI: 2001-514774/56.
XX
PT An isolated nucleic acid molecule encoding a fibroblast growth factor
PT 23 useful for treating autosomal dominant hypophosphatemic rickets -
XX
PS Example 1; Fig 2A-G; 158pp; English.
XX
XX The invention provides a human fibroblast growth factor (FGF)-23
CC polypeptide. The encoding DNA insert is contained in ATCC Deposit No.
CC PTA-1617. FGF-23 can be expressed by standard recombinant methodology.
CC The FGF-23 polypeptides, polynucleotides, modulators and antibodies are
CC useful for treating, preventing, or ameliorating an FGF-23 polypeptide-
CC related disease, condition or disorder especially autosomal dominant
CC hypophosphatemic rickets (ADHR). They are also useful for diagnosing a
CC pathological condition and for stimulating angiogenesis, promoting wound
CC healing and treating disorders of the liver. Sequences AAB85830-45
CC represent murine FGF protein sequences used for comparison studies with
CC human FGF-23.
XX
SQ Sequence 207 AA:

Query Match 98.5%; Score 1081; DB 22; Length 207;
Best Local Similarity 99.0%; Pred. No. 5,1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MYSAPSACTCLCLHFLLLCFQYQVLYAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTCLCLHFLLLCFQYQVLYAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIQVGRIRISARGEGDGYAQLVETDFGSOVRIRKGETEFLYLCMNRKGLVGRP 120
DB 61 TSGKHIQVGRIRISARGEGDGYAQLVETDFGSOVRIRKGETEFLYLCMNRKGLVGRP 120
QY 121 DGTSECVFIEKVLNNYATALMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYPK 180
DB 121 DGTSECVFIEKVLNNYATALMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYPK 180
QY 181 GQPELOKPKKYYTVTKRSRRIRPTHP 206
DB 181 GQPELOKPKKYYTVTKRSRRIRPTHP 206

RESULT 15
AAE04537
ID AAE04537 standard; Protein; 207 AA.
XX
AC AAE04537;
XX
DT 10-SEP-2001 (first entry)
XX
DE Mouse fibroblast growth factor (zFGF5).

XX Mouse; fibroblast growth factor-18; FGF-18; zFGF5; FGF receptor-2;
 KW FGF receptor-3; cytotoxin; cell proliferation inhibitor; tumour;
 KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
 KW thyroid carcinoma; osteosarcoma.
 XX
 OS Mus musculus.
 XX
 PN WO200139788-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 28-NOV-2000; 2000WO-US32380.
 XX
 PR 02-DEC-1999; 99US-0452977.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI West JW;
 XX
 DR WPI; 2001-417789/44.
 DR N-PSDB; AAD07796.
 XX
 PT Novel fibroblast growth factor targeting composition useful for
 PT inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
 PT receptor 2
 XX
 PS Claim 4; Page 61-62; 62pp; English.
 XX
 CC The present invention relates to methods for targetting cells that
 CC express fibroblast growth receptor-3 or -2. Fibroblast growth
 CC factor-18 (FGF-18) binds with FGF receptor-2 and -3. A targetting
 CC composition comprising FGF-18 component and cytotoxin, is useful for
 CC inhibiting the proliferation of cells that express FGF receptor-3 or
 CC -2, in a subject having tumour cells such as multiple myeloma cells,
 CC bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
 CC cells, osteosarcoma cells and intimal smooth muscle cells. The present
 CC sequence is mouse zFGF5 protein.
 XX
 SQ Sequence 207 AA;

Query Match 98.5%; Score 1081; DB 22; Length 207;
 Best local Similarity 99.0%; Pred. No. 5,1e-109;
 Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 MYSAPSACTGCLHFLLCFQVQVLAENVDERIHVENQTRADDVSRQRLRYQLYSR 60
 D1 1 MYSAPSACTGCLHFLLCFQVQVLAENVDERIHVENQTRADDVSRQRLRYQLYSR 60
 QY 61 TSGKHIOVLGRISARGEDDGYAQLLVETDTGSOYRIKGETEFLCMNRKGLVGP 120
 D1 61 TSGKHIOVLGRISARGEDDGYAQLLVETDTGSOYRIKGETEFLCMNRKGLVGP 120
 QY 121 DGTSEKCVFTEKVLNNYTLMSAKYSGWTVGFTKKGRPKRPKTRNODVHFMKRYPK 180
 D1 121 DGTSEKCVFTEKVLNNYTLMSAKYSGWTVGFTKKGRPKRPKTRNODVHFMKRYPK 180
 QY 181 GQAELOKPFKYTVTKRSRRIRPTHP 206
 D1 181 GQAELOKPFKYTVTKRSRRIRPTHP 206

Search completed: April 27, 2003, 15:03:24
 Job time : 46 secs

THIS PAGE BLANK (USPTO)